Get the Stockscreener App
653.45
0.65%
-4.52
Argen X Se Adr stock is traded at $653.45, with a volume of 105.48K.
It is down -0.65% in the last 24 hours and up +0.78% over the past month.
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
See More
Previous Close:
$657.97
Open:
$656.21
24h Volume:
105.48K
Relative Volume:
0.41
Market Cap:
$39.98B
Revenue:
$1.86B
Net Income/Loss:
$-40.29M
P/E Ratio:
-768.76
EPS:
-0.85
Net Cash Flow:
$-1.28B
1W Performance:
-0.22%
1M Performance:
+0.78%
6M Performance:
+31.48%
1Y Performance:
+66.78%
1-Day Range:
$650.78
$658.46
1-Week Range:
$648.49
$672.39
52-Week Range:
$349.86
$678.21
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.33 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.93 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-17-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Strong Buy |
| Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jul-25-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-31-23 | Initiated | Scotiabank | Sector Perform |
| Jul-24-23 | Downgrade | UBS | Buy → Neutral |
| Jul-17-23 | Resumed | Evercore ISI | Outperform |
| Jun-15-23 | Initiated | Societe Generale | Sell |
| May-31-23 | Initiated | UBS | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-07-22 | Initiated | William Blair | Outperform |
| Oct-12-22 | Initiated | Oppenheimer | Perform |
| Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-22 | Resumed | Stifel | Buy |
| May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-23-21 | Initiated | Deutsche Bank | Hold |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-18-21 | Initiated | UBS | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-23-21 | Initiated | Redburn | Neutral |
| Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
| Feb-10-20 | Initiated | BofA/Merrill | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-22-19 | Initiated | JP Morgan | Overweight |
| Sep-27-19 | Initiated | Wells Fargo | Market Perform |
| Sep-16-19 | Resumed | Cowen | Outperform |
| Jun-28-19 | Initiated | Robert W. Baird | Outperform |
| Jan-18-19 | Resumed | SunTrust | Buy |
| Jan-04-19 | Initiated | Morgan Stanley | Overweight |
| Dec-17-18 | Initiated | Goldman | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Jun-29-18 | Initiated | Nomura | Buy |
| Apr-09-18 | Initiated | SunTrust | Buy |
| Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
BBVA Argentina ADR (BBAR) Shares Rise Despite Market Challenges - The News Heater
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
argenx SE : The stock is approaching a major resistance level -January 29, 2025 at 04:11 am EST - Marketscreener.com
argenx's SWOT analysis: biotech stock soars on VYVGART success, pipeline promise - Investing.com India
Argenx stock price target raised to $717 by H.C. Wainwright - Investing.com India
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Truist Securities raises argenx stock rating to Buy, says will exceed Vision 2030 - Investing.com
Jefferies raises argenx stock target, reaffirms buy on global sales result - Investing.com
argenx's SWOT analysis: biotech stock soars on vyvgart success - Investing.com
Piper Sandler increases argenx stock price target on revised estimates - Investing.com
Argenx stock soars to all-time high of $645.31 amid robust growth - Investing.com
Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
Argenx stock soars to all-time high of $630.4 amid robust growth By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $630.4 amid robust growth - Investing.com
argenx's SWOT analysis: biotech stock soars on VYVGART success - Investing.com
Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - MSN
Argenx Expands Autoimmune Portfolio With Additional Vyvgart Approvals as Pipeline Develops - Morningstar
Piper Sandler maintains stock target on argenx, cites growth potential - Investing.com
Argenx stock soars to all-time high of $620.29 - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Argenx stock soars to all-time high of $612.64 amid robust growth By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $612.64 amid robust growth - Investing.com India
argenx's SWOT analysis: biotech firm's stock soars on VYVGART success - Investing.com
Jefferies reaffirms Buy rating on argenx stock, ups target amid promising trial updates - Investing.com India
Can Argenx stock sustain its autoimmune category dominance? Oppenheimer weighs in - Investing.com
Barclays bullish on argenx stock after positive trial results - Investing.com
Barclays bullish on argenx stock after positive trial results By Investing.com - Investing.com South Africa
argenx shares see price target boosted by Raymond James, Strong Buy rating upheld - Investing.com
10 Biggest Biotechnology Companies - Investopedia
Argenx upgraded at Wolfe on myasthenia gravis dominance - MSN
argenx stock boosted by Wolfe, citing dominance in MG and profitability ahead - Investing.com
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Yahoo Finance
Scotiabank raises argenx stock PT to $715, highlights efgartigimod's potential - Investing.com India
argenx SE's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
Deutsche Bank raises argenx target by EUR25, acknowledges momentum despite valuation - Investing.com
Argenx shares target raised by H.C. Wainwright, citing strong sales performance - Investing.com
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry' - Benzinga
Argenx shares target lifted, overweight on Vyvgart sales beat - Investing.com
argenx stock downgraded after 65% rally, Baird cites limited short-term upside - Investing.com India
William Blair bullish on argenx stock as Vyvgart flexes in CIDP and eyes new horizons - Investing.com India
Raymond James maintains outperform on argenx, cites strong sales - Investing.com India
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):